Stock Events

Stock Events

Decoy Therapeutics 

$6.25
42
-$0.36-5.45% Monday 20:00

Statistics

Day High
6.51
Day Low
5.63
52W High
415.8
52W Low
4.41
Volume
10,852
Avg. Volume
-
Mkt Cap
36.64M
P/E Ratio
0.08
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14AugExpected
Q3 2025
Q1 2026
Next
-403.2
-269.76
-136.32
-2.88
Expected EPS
-2.8848
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-11.15MNet Income

Analyst Ratings

2.50Average Price Target
The highest estimate is 2.50.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DCOY. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.97B
BioMarin Pharmaceutical develops and commercializes innovative therapies for rare genetic diseases, overlapping with Salarius' focus on rare cancers.
CRISPR Therapeutics
CRSP
Mkt Cap5.11B
CRISPR Therapeutics is involved in gene editing, a cutting-edge technology that could address cancer in ways competitive to Salarius' approach.
Novartis
NVS
Mkt Cap284.61B
Novartis offers a broad portfolio of oncology drugs, directly competing with Salarius Pharmaceuticals in the cancer treatment market.
Gilead Sciences
GILD
Mkt Cap160.36B
Gilead Sciences has a strong presence in oncology and cell therapy, areas that Salarius is also targeting.
AMGEN
AMGN
Mkt Cap188.67B
Amgen has a diverse oncology portfolio, including treatments for rare cancers, making it a direct competitor.
Pfizer
PFE
Mkt Cap148.41B
Pfizer has a large and expanding oncology division, competing across a range of cancer treatments, including those for rare cancers.
Merck
MRK
Mkt Cap298.33B
Merck is known for its cancer treatments, including immunotherapies that compete with Salarius' therapeutic approaches.
Regeneron Pharmaceuticals
REGN
Mkt Cap66.62B
Regeneron Pharmaceuticals, with its focus on innovative biologics for cancer treatment, competes in the same biopharmaceutical space as Salarius.

About

Decoy Therapeutics, Inc. is a preclinical-stage biotechnology company that is leveraging machine learning and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company is headquartered in Cambridge, MA.
Show more...
CEO
Mr. Frederick E. Pierce II
Employees
2
Country
United States
ISIN
US79400X6022

Listings

STU
DE
FP11.STU
MU
DE
FP11.MU
F
DE
FP11.F
XNAS
US
DCOY

0 Comments

Share your thoughts

FAQ

What is Decoy Therapeutics stock price today?▼
The current price of DCOY is $6.25 USD — it has decreased by -5.45% in the past 24 hours. Watch Decoy Therapeutics stock price performance more closely on the chart.
What is Decoy Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Decoy Therapeutics stocks are traded under the ticker DCOY.
What is Decoy Therapeutics market cap?▼
Today Decoy Therapeutics has the market capitalization of 36.64M
When is the next Decoy Therapeutics earnings date?▼
Decoy Therapeutics is going to release the next earnings report on August 14, 2026.
What is Decoy Therapeutics revenue for the last year?▼
Decoy Therapeutics revenue for the last year amounts to 0 USD.
What is Decoy Therapeutics net income for the last year?▼
DCOY net income for the last year is -11.15M USD.
How many employees does Decoy Therapeutics have?▼
As of June 09, 2026, the company has 2 employees.
In which sector is Decoy Therapeutics located?▼
Decoy Therapeutics operates in the Health & Wellness sector.
When did Decoy Therapeutics complete a stock split?▼
The last stock split for Decoy Therapeutics was on March 09, 2026 with a ratio of 1:12.
Where is Decoy Therapeutics headquartered?▼
Decoy Therapeutics is headquartered in Houston, United States.